SCHEMBL2749583

SCHEMBL2749583

Cc1ccn2nc(-c3ccccc3)cc2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.58
NPC1 O15118 8/20 0.58
KDM4E B2RXH2 6/20 0.58
MAPT P10636 3/20 0.57
ALDH1A1 P00352 5/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
HPGD P15428 4/20 0.55
NFKB1 P19838 1/20 0.55
HTT P42858 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
PDE10A Q9Y233 4/20 0.47
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
LMNA P02545 1/20 0.44
HCRTR1 O43613 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4148547 0.85 NPC1 (0.59) RAB9ANPC1KDM4EMAPTALDH1A1
SCHEMBL10279117 0.82 RAB9A (0.47) RAB9ANPC1KDM4EMAPTALDH1A1
SCHEMBL10236233 0.82 ALDH1A1 (0.58) RAB9ANPC1KDM4EMAPTALDH1A1
SCHEMBL545249 0.79 KDM4E (0.50) RAB9ANPC1KDM4EMAPTALDH1A1
SCHEMBL3348495 0.79 SMN1; SMN2 (0.46) RAB9ANPC1KDM4EMAPTALDH1A1
SCHEMBL5056983 0.77 RAB9A (0.54) RAB9ANPC1KDM4EMAPTALDH1A1
SCHEMBL1727061 0.76 LIPG (0.47) RAB9ANPC1KDM4EMAPTALDH1A1
SCHEMBL3564589 0.75 KDM4E (0.52) KDM4EMAPTALDH1A1HSD17B10TSHR
SCHEMBL1668742 0.75 RAB9A (0.51) RAB9ANPC1KDM4EMAPTALDH1A1
SCHEMBL13501410 0.74 PDE10A (0.40) RAB9ANPC1KDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586623-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-11-19 US disclosed
US-8518943-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-08-27 US disclosed
US-20120214815-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2012-08-23 US disclosed
US-20120196866-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2012-08-02 US disclosed
US-8183241-B2 2-oxo-1-pyrrolidine derivatives UCB PHARMA, S.A. (BE) 2012-05-22 US disclosed
US-8178533-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2012-05-15 US disclosed
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2009-12-17 US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214815-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 RAB9A 547/4885NPC1 416/4885KDM4E 1184/4885
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 RAB9A 547/4885NPC1 416/4885KDM4E 1184/4885
US-20120196866-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 RAB9A 547/4885NPC1 416/4885KDM4E 1184/4885
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES OPRD1, PPOX, CYP2D6 RAB9A 778/4885NPC1 404/4885KDM4E 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.